JPMorgan raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $517 from $515 and keeps an Overweight rating on the shares. The firm adjusted the company’s model ahead of the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals presents long-term data on CASGEVY
- Vertex Pharmaceuticals announces EC approval for Alyftrek for CF treatment
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Limited Uptake and Insurance Challenges for Journavx
- Cautious Hold Rating on Vertex Pharmaceuticals Amid Promising Diabetes Treatment and Market Uncertainties
- Hold Rating on Vertex Pharmaceuticals: Balancing Promising Efficacy with Scalability and Commercial Viability Concerns for Zimislecel Therapy